Daraxonrasib: How soon could the new drug for pancreatic cancer be available in the UK?

Pancreatic cancer is among the hardest types of cancer to treat, with a median overall survival of less than one year and a five-year survival rate of only about 5% of patients in the UK. Half of people die within three months of diagnosis, often because symptoms appear only in advanced stages when surgical removal is no longer possible. A new treatment approved by the US drug regulator for patients with metastatic pancreatic adenocarcinoma (PDAC) suggests a potential breakthrough. The drug, named daraxonrasib (marketed as Rasonque in the US), is considered one of the biggest developments in pancreatic cancer treatment in decades. It is a daily tablet belonging to a new generation of RAS inhibitors. Daraxonrasib works by blocking the KRAS protein, which becomes overactive.